We are live on ! Find out more
GNMK

GenMark Diagnostics, Inc
GNMK

Delisted

GNMK was delisted on the 21st of April, 2021.

Back to rankings

111 hedge funds and large institutions have $266M invested in GenMark Diagnostics, Inc in 2019 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 49 increasing their positions, 28 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 28

11% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 9

1% more funds holding

Funds holding: 110 → 111 (+1)

17% less capital invested

Capital invested by funds: $320M → $266M (-$53.9M)

Holders
111
Holders Change
+1
Holders Change %
+0.91%
% of All Funds
2.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
49
Reduced
28
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$5.79M
2
NIM
Needham Investment Management
New York
+$3.01M
3
Bank of America
Bank of America
North Carolina
+$2.35M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$2.04M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.96M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$4.89M
2
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans
Minnesota
-$2.49M
3
Millennium Management
Millennium Management
New York
-$1.86M
4
MAG
Millrace Asset Group
Pennsylvania
-$1.6M
5
Citadel Advisors
Citadel Advisors
Florida
-$1.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
Royal Bank of Canada
101
Royal Bank of Canada
Ontario, Canada
$8K +$9.41K +1,706 +42,650%
LTFS
102
Ladenburg Thalmann Financial Services
Florida
$5K -$17.6K -3,195 -76%
PCM
103
Prelude Capital Management
New York
$4K -$794 -144 -15%
PHK
104
Point72 Hong Kong
Hong Kong
$4K +$4.47K +811 New
CSS
105
Cubist Systematic Strategies
Connecticut
$3K -$77.3K -14,011 -96%
CAC
106
Certified Advisory Corp
Florida
$2K – – –
SSB
107
Sandy Spring Bank
Maryland
$2K – – –
SIM
108
Sonora Investment Management
Arizona
$2K – – –
SFS
109
Sowell Financial Services
Arkansas
$1K – – –
RE
110
RBC Europe
United Kingdom
$265 – – –
Thrivent Financial for Lutherans
111
Thrivent Financial for Lutherans
Minnesota
– -$2.49M -410,483 Closed
MAG
112
Millrace Asset Group
Pennsylvania
– -$1.6M -264,348 Closed
Susquehanna International Group
113
Susquehanna International Group
Pennsylvania
– -$147K -24,302 Closed
ECM
114
ExodusPoint Capital Management
New York
– -$98K -16,156 Closed
GCP
115
GSA Capital Partners
United Kingdom
– -$89K -14,632 Closed
TI
116
Trexquant Investment
Connecticut
– -$67K -11,052 Closed
Victory Capital Management
117
Victory Capital Management
Texas
– -$42K -6,880 Closed
HI
118
Hudock Inc
Pennsylvania
– -$13K -2,200 Closed
Simplex Trading
119
Simplex Trading
Illinois
– -$9K -1,612 Closed
GT
120
Glenmede Trust
Pennsylvania
– -$5.52K -1,000 -98%
1 2 3 4
5

GNMK Hedge Fund Activity: Q4 2019 in Review

111 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in GenMark Diagnostics, Inc (GNMK) for Q4 2019, worth a combined $266M — down 17% from $320M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new GNMK positions and 9 closed out — a net gain of 1 holder — while 49 added to existing stakes and 28 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $5.79M. The largest seller was T. Rowe Price Associates, cutting an estimated $4.89M.

  • 111 institutional investors held GenMark Diagnostics, Inc (GNMK) as of Q4 2019, up from 110 in Q3 2019.
  • Funds reported $266M of GenMark Diagnostics, Inc stock for Q4 2019, down 17% quarter-over-quarter.
  • 10 funds opened new GenMark Diagnostics, Inc positions in Q4 2019 and 9 closed out, a net change of +1 holder.
  • The largest GenMark Diagnostics, Inc buyer in Q4 2019 was Morgan Stanley, an estimated $5.79M added.
  • The largest GenMark Diagnostics, Inc seller in Q4 2019 was T. Rowe Price Associates, an estimated $4.89M sold.

Based on aggregated 13F filings for Q4 2019.